



THE AGA KHAN UNIVERSITY

eCommons@AKU

Internal Medicine, East Africa

Medical College, East Africa

February 2012

The influence of antiretroviral therapy on the QTc interval in an African cohort

J. Shavadia
Aga Khan University

Reena Shah
Aga Khan University, reena.shah@aku.edu

Gerald Yonga
Aga Khan University, gerald.yonga@aku.edu

R. Patel
Chelsea and Westminster Hospital

J. Stebbing
Chelsea and Westminster Hospital

See next page for additional authors

Follow this and additional works at: http://ecommons.aku.edu/eastafrica_fhs_mc_intern_med

 Part of the [Cardiology Commons](#), and the [Other Medical Specialties Commons](#)

Recommended Citation

Shavadia, J., Shah, R., Yonga, G., Patel, R., Stebbing, J., Nelson, M. (2012). The influence of antiretroviral therapy on the QTc interval in an African cohort. *Clinical Infectious Diseases*, 54, 448-449.

Available at: http://ecommons.aku.edu/eastafrica_fhs_mc_intern_med/9

Authors

J. Shavadia, Reena Shah, Gerald Yonga, R. Patel, J. Stebbing, and M. Nelson

The Influence of Antiretroviral Therapy on the QTc Interval in an African Cohort

TO THE EDITOR—Cardiovascular disease in human immunodeficiency virus (HIV) infection encompasses a wide range of pathologic entities, including myocardial, pericardial, and endocardial disease, atherosclerosis, arrhythmias, and vasculitis. The most common manifestations of HIV-associated heart disease in sub-Saharan Africa are pericarditis, cardiomyopathy, and pulmonary hypertension [1]. Coronary artery disease, lipodystrophy, and metabolic syndrome, although common in developed countries, are traditionally thought to be less clinically significant problems in the African subcontinent [2]. It is well known that prolongation of the QT_c interval can predispose patients to potentially fatal ventricular tachyarrhythmias, particularly torsades de pointes, and thus is an independent predictor of cardiovascular morbidity and mortality [3].

The aim of this study was to determine whether there is an association between antiretroviral (ARV) therapy and prolonged QT in HIV-positive ARV-treated patients in Nairobi, Kenya. HIV-positive adults from both inpatient and outpatient departments at Aga Khan Teaching Hospital, Nairobi, were enrolled with exclusion criteria including any known cardiac disease. Patients were enrolled into either the “ARV-experienced” or “ARV-naive” arm of the study. The study was approved by the local ethics committee, and written informed consent obtained from all patients.

A standard 12-lead electrocardiogram was obtained in each patient, and a QT_c interval of >440 ms was considered prolonged. A total of 299 HIV-positive patients were screened, 157 in the ARV-experienced arm and 142 in the ARV-naive control arm. A total of 27 patients in the ARV-experienced arm and 12 in the ARV-naive arm were excluded due to protocol violations, leaving 130 patients in each arm of the study (Table 1). QT_c interval prolongation was observed in 16.2% of patients in the ARV-experienced group, compared with 6.9% in the ARV-naive control group ($\chi^2 = 5.43$; $P = .01$); the odds ratio was calculated as 2.5 with a 95% confidence interval (1.01–6.67; $P = .02$). The overall prevalence of QT_c prolongation across the whole subject cohort (ARV-experienced and ARV-naive) was 11.5%. When patients were divided by sex, prolongation was observed in 11.3% of male and 11.8% of female patients. The majority of patients with QT_c prolongation had QT_c intervals of 440–469 ms, and none had QT_c intervals >500 ms (Table 2). There did not appear to be any significant difference in prevalence of QT_c prolongation between patients receiving a nonnucleoside analogue reverse-transcriptase inhibitor–based regimen and those receiving a protease inhibitor–based regimen ($P = .78$). In addition, there was no significant difference in prevalence of QT_c prolongation between patients with World Health

Organization stage I/II HIV infection and those with stage III/IV infection ($\chi^2 = 0.52$; $P = .47$), nor were there correlations with CD4 cell count ($r = -0.043$), in contrast to findings of other studies [4–6].

Literature on the association of QT_c prolongation and ARV therapy is surprisingly sparse [7–10]. Our study shows that ARV therapy does appear to confer a significant increased risk of QT_c prolongation in HIV-positive patients, compared with ARV-naive controls. The increased risk has the potential to predispose otherwise medically stable patients to the development of potentially fatal ventricular arrhythmias, although the exact significance of an acquired asymptomatic QT_c prolongation in clinical practice is yet to be established.

These results should remind physicians of the importance of measuring and monitoring the QT_c interval for patients receiving ARV therapy and tailoring management accordingly, to successfully minimize cardiovascular morbidity and mortality as ARV drugs become readily available.

Notes

Acknowledgements. We thank Dr Jowi and Dr Sitna for their valuable critique of the paper.

Financial support. This work was supported by the Research Support Unit of Aga Khan University Hospital, Nairobi, Kenya.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

J. Shavadia,¹ R. Shah,¹ G. Yonga,¹ R. Patel,² J. Stebbing,² and M. Nelson²

¹Departments of HIV Medicine and Cardiology, Aga Khan University Hospital, Nairobi, Kenya; and

²Department of HIV Medicine, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom

References

1. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African

Table 1. Baseline Characteristics of Study Patients

Patient characteristic	ARV-experienced patients	ARV-naive patients	<i>P</i>
Age, mean ± SD (range), y	42.0 ± 8.15 (23–72)	42.5 ± 8.17 (27–84)	.60
Sex ratio, M-F	0.97:1	1:1.13	.62
Weight, mean ± SD (range), kg	67.4 ± 12.8 (42–123)	66.9 ± 15.0 (40–112)	.77
Hypertension, no. (%)	30 (23.1)	34 (26.2)	.67
Diabetes mellitus, no. (%)	4 (3.1)	7 (5.4)	.54
Excess alcohol intake, no. (%)	1 (0.8)	12 (9.2)	.004
Current smoker, no. (%)	1 (0.8)	9 (6.9)	.02
CD4 cell count, mean ± SD, cells/mm ³	344 ± 269 (4–1308)	288 ± 331 (3–2000)	.14
Mean potassium level, mean ± SD, mmol/l	3.9 ± 0.47	4.0 ± 0.46	.09
eGFR, mean ± SD, mL/min	90.7 ± 23.7	83.9 ± 18.9	.03

Abbreviations: ARV, antiretroviral; eGFR, estimated glomerular filtration rate; SD, standard deviation.

- perspective. *Nat Clin Pract Cardiovasc Med* **2009**; 6:120–7.
- Magula NP, Mayosi BM. Cardiac involvement in HIV-infected people living in Africa: a review. *Cardiovasc J S Afr* **2003**; 14:231–7.
 - Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. *Am J Ther* **2010**; 17:e193–201.
 - Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. *J Natl Med Assoc* **2005**; 97:1657–61.
 - Okeahialam BN, Sani MU. Heart disease in HIV/AIDS: how much is due to cachexia? *Afr J Med Sci* **2006**; 35(Suppl):99–102.
 - Qaqa AY, Shaaban H, DeBari VA, et al. Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: a cohort-nested case-control study in an outpatient population. *Cardiology* **2010**; 117:105–11.
 - Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. *Lancet* **2005**; 365:682–6.
 - Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. *J Infect* **2007**; 54:597–602.
 - Damle B, Fossier C, Ito K, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. *J Clin Pharmacol* **2009**; 49:291–300.

- Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. *AIDS* **2011**; 25:367–77.

Correspondence: Justin Stebbing, MA, FRCP, FRCPATH, PhD, Department of HIV Medicine, Imperial College, London SW10 9NH, UK (j.stebbing@imperial.ac.uk).

Clinical Infectious Diseases **2012;54(3):448–9**

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cir712